Dealing with hERG liabilities early: Diverse approaches to an important goal in drug development

British Journal of Pharmacology

Volumn 159, Issue 1, 2010, Pages 22-24

  Guth, B D ^a   Rast, G ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

HERG; Integrated risk assessment; QT interval prolongation

Indexed keywords

POTASSIUM CHANNEL HERG;

DRUG DESIGN; DRUG TARGETING; EXPERIMENTAL STUDY; HUMAN; METHODOLOGY; NONHUMAN; NOTE; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; SCREENING;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; LONG QT SYNDROME; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT;

EID: 74549132785     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00265.x     Document Type: Note

References (1)

1. Pollard DE, Gerges NA, Bridgland-Taylor MH, Easter A, Hammond T, Valentin J-P (2010). An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. Br J Pharmacol 159 : 12 21.